The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.
 
Wenbo Tang
No Relationships to Disclose
 
Ye Guo
Research Funding - Hutchison MediPharma; Innovent Biologics, Inc
 
Liqiong Xue
No Relationships to Disclose
 
Wei Peng
No Relationships to Disclose
 
Xiaoxiao Ge
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Wei Wei
Employment - Shanghai Jia Tan Pharmatech
 
Juncai Xu
Employment - Shanghai Jia Tan Pharmatech
Research Funding - Shanghai Jia Tan Pharmatech (Inst)
 
Yongguo Li
Employment - Shanghai Jia Tan Pharmatech
Research Funding - Shanghai Jia Tan Pharmatech (Inst)
 
Jin Li
Research Funding - Shanghai Jia Tan Pharmatech (Inst)